Archives

Leveraging Conditional Activation to Localize Antibody Drug Conjugates to the Tumor

Marcia Belvin Ph.D. Presented at World ADC, October 16-19, 2023, San Diego, California.

Learn More

Tailoring the Selection of Target, Payload, and Tumor Type to Maximize the Therapeutic Index of Conditionally Activated ADCs

Marcia Belvin, SVP, Head of Research

Learn More

CX-2043, an EpCAM-Targeting Probody Drug Conjugate, Demonstrates Anti -Tumor Activity with a Favorable Safety Profile in Preclinical Models

Bob Y. Liu, Joel Shen, Wendy Yu, Chaoran Jing, Sharmi Saha, Vangipuram Rangan, Jennifer Richardson, Yimao Liu, Steven Boule, Jacquelynn Lucas, Olga Ab, Stuart Hicks, W. Michael Kavanaugh, Siew Schleyer, Marcia Belvin. Poster presented at the 32nd EORTC-NCI-AACR Symposium, October 24-25, 2020.

Learn More